The Clorox Company $CLX Stock Position Decreased by Amundi

Key Points

• Amundi reduced its stake in The Clorox Company by 9.9%, now owning 930,291 shares valued at $138.3 million.
• Several institutional investors increased their positions in Clorox, with Adage Capital raising its stake by 97.8%.
• Clorox's recent earnings report showed an EPS of $2.87, exceeding expectations, and the company announced a quarterly dividend increase to $1.24 per share.

Amundi cut its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 9.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 930,291 shares of the company's stock after selling 101,992 shares during the period. Amundi owned 0.75% of Clorox worth $138,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its stake in shares of Clorox by 97.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 112,453 shares of the company's stock worth $16,559,000 after purchasing an additional 55,600 shares in the last quarter. EP Wealth Advisors LLC raised its stake in shares of Clorox by 3.5% in the 1st quarter. EP Wealth Advisors LLC now owns 7,103 shares of the company's stock valued at $1,046,000 after acquiring an additional 243 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its stake in shares of Clorox by 66.4% in the 1st quarter. Focus Partners Advisor Solutions LLC now owns 8,984 shares of the company's stock valued at $1,323,000 after acquiring an additional 3,586 shares in the last quarter. Flputnam Investment Management Co. raised its stake in shares of Clorox by 32.9% in the 1st quarter. Flputnam Investment Management Co. now owns 12,132 shares of the company's stock valued at $1,786,000 after acquiring an additional 3,003 shares in the last quarter. Finally, ICW Investment Advisors LLC raised its stake in shares of Clorox by 1.1% in the 1st quarter. ICW Investment Advisors LLC now owns 10,265 shares of the company's stock valued at $1,512,000 after acquiring an additional 110 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CLX has been the topic of a number of recent analyst reports. UBS Group cut their price objective on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Morgan Stanley cut their price objective on Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. JPMorgan Chase & Co. cut their price objective on Clorox from $144.00 to $140.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Finally, Wells Fargo & Company dropped their price target on Clorox from $138.00 to $130.00 and set an "equal weight" rating on the stock in a research report on Friday. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus target price of $142.64.

Clorox Stock Performance

Shares of NYSE CLX opened at $127.08 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The business's 50 day moving average is $124.17 and its two-hundred day moving average is $133.47. The company has a market cap of $15.54 billion, a P/E ratio of 19.49, a P/E/G ratio of 1.00 and a beta of 0.52. The Clorox Company has a 12 month low of $116.53 and a 12 month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, equities analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Wednesday, August 13th were given a dividend of $1.24 per share. This is a boost from Clorox's previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Wednesday, August 13th. Clorox's dividend payout ratio (DPR) is presently 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.